This technical reference documents the assisted reproductive techniques of the horse — artificial insemination (AI) with fresh, cooled and frozen semen, embryo transfer (ET), ovum pick-up (OPU), ICSI-based in vitro embryo production, conventional equine IVF, oocyte transfer and cloning — for breeders, veterinarians, embryologists and laboratory teams. It is a professional orientation and quality framework, not a substitute for hands-on training, for a program’s own SOPs, or for veterinary judgment. It is deliberately not a controlled procedure manual in the SOP sense: it does not assign authorized personnel, prerequisites, stop criteria, acceptance limits or adverse-event handling — those belong to each program’s own SOP system, for which this reference supplies the evidence base and quality checkpoints.

Each section states the purpose of the technique, its physiological basis, the procedure as practiced, the quality checkpoints that separate consistent programs from inconsistent ones, and the sources that carry the authority for what is said. Sources are cited by register number (S1–S94); the companion Animal ART Source Register documents each one’s full citation, verification method and quality tier. The bovine equivalent of this reference is published separately — and the two make an instructive pair, because the mare’s biology (no practical superovulation, a single dominant follicle, a late-descending capsule-enclosed embryo) explains why equine ART took a different road from cattle.

Equine germplasm work sits inside a layered framework. At the top, the WOAH Terrestrial Animal Health Code (current online edition, updated 5 September 2025; archived edition of record: 32nd ed., 2024) sets the international trade standards: Chapter 4.6 for semen collection, processing and storage (updated 2024, covering equids), Chapter 4.8 for in vivo derived embryos of livestock and equids, Chapter 4.9 for oocytes and in vitro produced embryos of livestock and horses, Chapter 4.10 for micromanipulated embryos, and Chapter 4.12 for somatic cell nuclear transfer in production livestock and horses. These chapters embed the IETS/HASAC disease-risk categorization.

Regionally, the EU operates under Regulation (EU) 2016/429 (the Animal Health Law) with Commission Delegated Regulation (EU) 2020/686 as the operative standard for equine semen collection centres, embryo collection teams and embryo production teams. In the United States, 9 CFR Part 98 governs imports — including embryos of horses and asses and imported semen — while exports follow the importing country’s requirements as compiled in APHIS IREGS. Professional-body guidance completes the picture: AAEP infectious-disease guidelines where breeding commerce meets disease control (§4), and the IETS Manual as the procedural and certification standard for embryo handling.

A program does not choose between these layers; it inherits all of them that apply to its market. The practical rule: identify the destination of every straw and embryo before it is produced, because the destination determines the applicable certification path — and in the horse world, the destination registry matters too, since breed registries differ on which ART they accept (§18).

Every straw and embryo must be identifiable from collection to transfer, and every identity claim must be reconstructible from records. For embryos, the IETS Manual defines the labeling and certificate system — the Certificate of Embryo Recovery (form A), the combined recovery/IVM-IVF certificate for in vitro produced embryos (form A1), and the Certificate of Freezing (form C) — with straw codes tying each embryo to donor mare, stallion, collection date and freeze data. Stallion-semen straws carry standardized identification from the freezing center; the shipment’s paperwork ties straws to stallion, collection date and post-thaw specification (§9).

Minimum record content for any equine ART event: donor mare and stallion identity; date and method of collection or production; cycle records (follicle tracking, induction timing, ovulation date — the working clock of §6–8); batch/lot identity of media and semen used; operator identity; outcome (embryo recovered, stage, diameter, grade, disposition); and storage location down to tank, canister and cane. Registry rules add a second identity layer: parentage verification and the registry’s position on AI, ET, ICSI and cloning offspring belong in the client file before work begins.

The IETS/HASAC sanitary framework — sequential embryo washing under an intact zona pellucida, embedded in WOAH Code Chapter 4.8 for livestock and equids — is the backbone of embryo biosecurity in the horse, but its assurances do not transfer wholesale from cattle. WOAH Article 4.8.7 cautions that trypsin treatment is "not always beneficial and it should not be regarded as a general disinfectant," that it is warranted only where the pathogens of concern require it, and that it "may also have adverse effects on embryo viability, for instance in the case of equine embryos where the embryonic capsule could be damaged by the enzyme" [S2]. Equine sanitary processing therefore follows the species-appropriate WOAH and IETS provisions rather than defaulting to the bovine ten-wash/trypsin routine; the equine particulars — the acellular capsule (§11), and separate WOAH chapters for in vitro produced and micromanipulated embryos (4.9, 4.10) — are part of the certification picture, not footnotes to it.

On the semen side, the exemplar disease of stallion commerce is equine viral arteritis: EVA can be transmitted in cooled and frozen semen, and the AAEP guidelines set out carrier-stallion management, vaccination of at-risk stallions, and screening of imported semen. A breeding program treats EVA status as part of every stallion contract and every imported shipment’s paperwork.

Operationally: separate clean and contaminated flows; one embryo-handling pipette never returns to a common medium; flush fluids and recovered embryos are treated as biosecure material; and every export lot follows the exact processing protocol its certificate claims.

ART outcomes are equipment-stable before they are operator-brilliant. The core QC surfaces of an equine program:

• Thermal control. Warming stages, incubators, semen and embryo shipment containers are monitored and validated; cooled-transport logistics (semen §7, embryos §12) run on validated passive cooling devices, and every shipment’s evaluation on arrival is recorded and reported back.
• Liquid nitrogen storage. Tanks are inventoried, level-monitored and alarmed; storage location records match the physical tank map (§3).
• Media and consumables. Lot numbers recorded; expiry respected; commercial media and extenders handled per manufacturer instructions. Supplier protocols document intended use but are commercial sources — corroborated here against Tier A/B literature wherever cited.
• Semen analysis. Warmed-stage motility as the field standard; where CASA is used, instrument settings are documented and kept constant between comparisons.
• Competency. ICSI and micromanipulation carry long individual learning curves — laboratory operator qualification is part of the quality system (§15), and structured per-technique sign-off applies barn-side as much as lab-side.

The mare is a seasonally polyestrous long-day breeder: cyclicity concentrates in spring and summer, flanked by transitional periods and winter anestrus in most mares at temperate latitudes. The estrous cycle runs approximately 21–22 days [S48] with a long estrus (several days) ending in ovulation of a single dominant follicle in the great majority of cycles; the equine ovary ovulates only through the ovulation fossa, and the preovulatory follicle is large (commonly cited in the region of 35 mm and above when induction is considered) [S43]. Transrectal ultrasonography of follicles, uterine edema and the corpus luteum — the methodology Ginther's work established — is the working language of mare management.

Cycle control tools: artificial photoperiod to advance the first ovulation of the year; PGF2α for luteolysis after day ~5 of diestrus; and ovulation induction with hCG or the GnRH analog deslorelin once the follicle and edema indicate readiness — the scheduling backbone of AI with cooled and frozen semen (§7–8) and of donor/recipient coordination (§12).

Two physiological facts organize equine ART: reliable superovulation is not commercially available in the mare (attempts with equine FSH produced modest, inconsistent multiple ovulations), so in vivo work is one-embryo-per-cycle; and the equine embryo enters the uterus late (about day 5.5–6 after ovulation) wrapped in a unique glycoprotein capsule (§11). Together these explain why the industry's growth engine moved to OPU-ICSI (§14–15).

Mare-side AI management is ovulation-timing management: teasing records and serial ultrasound identify the developing follicle; ovulation is induced when follicle size and endometrial edema indicate readiness; and insemination is scheduled so that viable sperm await the ovum. With fresh or properly cooled semen — which retains fertility for on the order of 24–48 h [S46] — a single well-timed insemination before ovulation is standard practice, with re-insemination per program SOP if ovulation is delayed.

The widely used dose standard for fresh/cooled AI, per Samper and the McKinnon reference: approximately 500 million progressively motile sperm delivered into the uterine body [S46], with the semen extended in a suitable extender and — for transported semen — cooled at a controlled rate and shipped in a validated passive cooling container. On arrival, cooled semen is evaluated (motility on a warmed stage) and inseminated without re-warming delays; the shipment's evaluation result is recorded and reported back to the stallion side, because transported-semen programs live or die on closed feedback loops between collection and mare barn.

Post-ovulation management: confirm ovulation by ultrasound; examine for post-breeding intrauterine fluid, and treat susceptible mares per veterinary direction — post-breeding endometritis management is a core determinant of per-cycle pregnancy rate in problem mares.

Frozen stallion semen decouples breeding from the stallion's location and lifetime, at the price of shorter post-thaw longevity and larger between-stallion variation than in cattle. Management responds by tightening ovulation targeting: programs breed close to ovulation — commonly by timed insemination following induction, or by frequent ultrasound so insemination lands in the hours around ovulation (post-ovulation insemination within about 6 h is a documented strategy) [S43]. Thawing follows the freezing center's specified protocol exactly; dose is the center's specified straw set, evaluated post-thaw and recorded. Deep-horn (deep uterine) insemination onto or near the papilla, transrectally guided, is documented AAEP-level technique for frozen doses.

Low-dose insemination is the equine-specific refinement pioneered by Morris & Allen: hysteroscopic or deep-horn deposition directly onto the uterotubal papilla permits conception with doses far below conventional — reported down to the low millions of progressively motile sperm [S62] — which is what makes scarce frozen stock, poor freezers, and sex-sorted stallion semen usable. It demands more skill and equipment than body insemination and belongs in programs equipped to execute it.

Stallion variation is the planning constant: per Loomis & Graham's commercial dataset, individual stallions differ systematically in cryosurvival [S66], and customized freezing protocols (§9) plus stallion-specific dose validation are the professional response — a mare program should demand the center's post-thaw standards and per-stallion guidance with every shipment.

Collection uses an artificial vagina with a phantom (or live mount) under a consistent handling routine; gel fraction is excluded; and the ejaculate is immediately protected from cold shock, light and contamination. Baseline evaluation: volume, concentration, total and progressive motility (warmed stage; CASA where used, under documented settings), and morphology — with longitudinal records per stallion, because a stallion's own baseline is the reference that makes any single ejaculate interpretable.

For cooled shipment, semen is extended in a validated extender to protect sperm during 5 °C-range transport (§7). For freezing: extension in a cryoprotectant-bearing freezing extender, packaging in straws, controlled-rate cooling and freezing, and storage in liquid nitrogen — with the decisive practical fact being stallion-to-stallion variation in cryosurvival. The commercial state of the art (Loomis & Graham) is per-stallion protocol customization and honest post-thaw quality controls, with test-freezes before a stallion's stock is marketed. Extender systems from the Botucatu lineage are widely used commercially for both cooling and freezing; as commercial sources their instructions are followed per product and corroborated against the peer-reviewed record.

Health controls ride alongside (§4): EVA status and vaccination management per AAEP guidance are integral to stallion semen commerce, not an afterthought.

The equine embryo descends into the uterus around day 5.5–6 after ovulation; commercial recovery is by transcervical uterine lavage on day 7 or 8 post-ovulation [S47] (day 6.5 embryos are small morulae/early blastocysts; day 8+ embryos are large expanded blastocysts with consequences for cryopreservation, §13). Technique, per the McCue & Squires monograph and CSU-lineage practice: a cuffed catheter through the cervix; the uterus filled and drained with warmed flush medium in repeated cycles (the mare's uterus is lavaged as a whole, unlike the cow's horn-by-horn flush); effluent through an embryo filter; recovery of fluid accounted; the filter searched, and the embryo — usually one — washed, evaluated (§11) and dispositioned: transferred fresh, packaged for cooled shipment to a recipient station (§12), or vitrified (§13).

Because there is no commercial superovulation (§6), per-cycle arithmetic governs programs: published per-flush recovery from normal donor cycles runs on the order of one embryo in roughly half to three-quarters of attempts [S57], varying with donor age and fertility — the AAEP how-to literature (Hudson & McCue) is devoted to defending exactly that recovery rate through donor management, flush technique and timing. Older, subfertile donors recover fewer and lower-quality embryos; for those mares, oocyte-based techniques (§14–15, §17) took over clinically.

Equine embryos are evaluated on stage and morphological quality using the same conceptual scheme as bovine work (IETS-style stage and quality grading applied to equine stages: morula, early blastocyst, expanded blastocyst), with two equine particulars. First, size: the day-7 to day-8 equine blastocyst spans a wide diameter range, and diameter is measured and recorded because it drives cryopreservation options (§13) — embryos beyond roughly 300 µm vitrify poorly without intervention [S67]. Second, the capsule: from the blastocyst stage the equine conceptus is enclosed in an acellular glycoprotein capsule unique to equids; it is essential to early conceptus survival and shapes how the embryo tolerates manipulation — handling, biopsy and cryopreservation practice in the horse is capsule-aware in a way bovine work never has to be.

Evaluation discipline mirrors the bovine standard (see the companion Bovine Reproduction Technical Reference): controlled temperature, prompt assessment, per-embryo records of day, diameter, stage and grade; and the grade travels with the embryo on its paperwork, including the IETS-format certificates when embryos move commercially or internationally.

Equine recipient synchrony is managed around ovulation dates: the conventional acceptable window places the recipient's ovulation from about one day before to about three days after the donor's [S47], with programs defining their preferred sub-window by embryo age at transfer; recipient suitability further requires normal uterine tone and edema pattern for stage, a functional CL (or a pharmacologically supported alternative per veterinary direction), and the temperament and condition to carry and raise the foal. Large recipient herds under a single management system are the structural reason commercial-scale equine ET concentrated where it did.

Cooled embryo shipment is routine and changed the industry's geography: the flushed embryo is packaged in buffered holding medium and shipped in a validated passive cooling container to a recipient station for next-day transfer — the same logistics platform as cooled semen (§7), applied to embryos, per the McCue & Squires monograph.

Transfer is transcervical, atraumatic, and minimal: the embryo loaded in a small volume, the gun guarded through the cervix, deposition in the uterine body/horn per program technique, with asepsis and speed as the two quality variables. Per-transfer pregnancy outcomes are tracked by embryo age, size, cooled-vs-fresh, and recipient synchrony class — the stratification identifies whether losses are embryo-side or recipient-side.

Equine embryo freezing lagged bovine work for a physical reason: the successful equine embryo is recovered late, large, capsule-enclosed and fluid-filled, and large expanded blastocysts survive conventional cryopreservation poorly. The field's working solutions: (1) recover early — day 6.5–7 small embryos (under the ~300 µm threshold) vitrify well without intervention; (2) for expanded blastocysts, collapse the blastocoel (micromanipulation aspiration of blastocoel fluid) before vitrification — the approach documented at clinical scale by Choi & Hinrichs [S67], applicable to both in vivo and ICSI-produced embryos; and (3) in the OPU-ICSI pipeline (§15), vitrify at the small in vitro blastocyst stage, where cryotolerance is excellent — the practice that made "embryo banking" standard in equine IVP programs (Stout; Claes & Stout).

Operationally: vitrification media and devices per validated SOP and manufacturer protocol; embryo diameter measured and recorded before the decision; warming at the transfer end per the matching protocol; and outcome tracking by embryo size class, because the size–survival relationship is the technique's central quality lever.

Equine OPU is transvaginal ultrasound-guided aspiration adapted to mare-specific biology: in the dominant clinical model, all visible follicles are aspirated regardless of size [S56], yielding immature oocytes for in vitro maturation, on a schedule that repeats roughly every couple of weeks year-round without regard to cycle stage — the property that turned the mare's one-embryo-per-cycle constraint (§6) into a solved problem. The equine follicle holds its cumulus–oocyte complex tightly; aspiration therefore uses needle systems and follicle-flushing/scraping technique per program SOP, and per-session oocyte recovery is counted against follicles punctured as the operator's core metric.

Recovered immature oocytes tolerate holding and overnight shipment at controlled temperature to centralized ICSI laboratories — the hub-and-spoke structure of the commercial equine IVP industry, documented in the Hinrichs and Stout program literature. Donor-side management (sedation, per-session care, session spacing, complication surveillance) follows veterinary SOP; the technique is established, routine practice in healthy donors under experienced operators.

Because conventional IVF failed in the horse for three decades (§16), the equine in vitro industry was built on intracytoplasmic sperm injection: one sperm injected into each matured oocyte. The clinical pipeline, per Hinrichs and the Utrecht program literature: OPU-recovered immature oocytes (§14) are matured in vitro (a longer IVM than cattle, on the order of a day or more per published systems); matured oocytes are injected — a single straw of frozen semen, cut and used sparingly, can serve many oocytes, which is why ICSI rescued limited and deceased-stallion stock; injected oocytes are cultured 7–10 days to the blastocyst stage [S56]; and blastocysts are transferred fresh where logistics allow or, routinely, vitrified for later transfer (§13).

The first equine ICSI pregnancy was reported by Squires et al. (1996) [S52] at Colorado State — the resulting foal was the first produced by ICSI — and the technique's clinical maturation is documented across the Hinrichs, Galli/Avantea and Utrecht literatures. Program-level outcome reporting follows Claes & Stout's model: oocytes per session, maturation rate, blastocyst rate per injected oocyte, and foal rate per transferred embryo, each against the program's rolling baseline. Equipment (micromanipulators, injection systems) and media follow the laboratory's validated SOPs; ICSI is a laboratory discipline with a long individual learning curve, and operator qualification is part of the quality system.

Scale context from the verified IETS statistics: equine embryo activity recorded for 2024 totaled 40,862 embryos [S9], with IVP (15,867) still below in vivo recovery (24,995) but structurally growing — the mare is the second species after cattle where in vitro production is reshaping the industry.

For thirty years, standard co-incubation IVF — the technique that industrialized in cattle — did not work in the horse: stallion sperm would not reliably capacitate in vitro, and the mare's "IVF problem" stood as the field's defining open question. It was resolved by Felix, Turner, Dobbie & Hinrichs (2022): prolonged sperm pre-incubation under defined capacitating conditions yielded reported fertilization around 74% [S55], blastocyst development, and live foals from a repeatable, standard IVF procedure (published with a 2023 correction, cited alongside per the register).

Status for practice, per the register's currency notes: the breakthrough system was validated with fresh semen, with adaptations to frozen semen reported subsequently by the same research lineage; clinical adoption is in its early growth phase alongside the established ICSI infrastructure (§15). A program considering conventional equine IVF today evaluates it as an emerging alternative whose published protocol is precise about sperm handling — the capacitation conditions are the technique — and whose outcome benchmarks are still accumulating in the literature.

The teaching value is larger than the technique: equine IVF failed for decades not because the oocyte was inadequate but because sperm physiology was unmet. When a technique fails in a new species, the portable lesson is to ask which gamete's biology the protocol was silently assuming.

Oocyte transfer moves a donor mare's oocyte into the oviduct of a young, fertile recipient who is then inseminated — outsourcing not the pregnancy (as in ET) but the oviductal environment and the uterus at once. Developed clinically by Carnevale at Colorado State, it served a defined population: aged or subfertile donor mares whose oocytes remained competent while their reproductive tract was the limiting factor. GIFT (gamete intrafallopian transfer) places oocyte and sperm together in the recipient's oviduct, historically relevant when in vitro fertilization options were absent. The Carnevale clinical series documents the technique's real-world success factors: donor age effects on oocyte competence dominate outcomes, and recipient quality and timing discipline do the rest.

Current standing, stated plainly per the register: oocyte transfer and GIFT have been largely displaced clinically by OPU-ICSI (§15), which achieves the same donor-side goal with less recipient surgery-adjacent logistics and adds embryo banking. They remain in the reference because the published record is instructive, occasional indications persist, and a credible manual reports the field's history honestly rather than silently.

Equid cloning arrived in 2003 twice within a season: the first cloned equid was the mule Idaho Gem (Woods et al., Science, published May 2003), and the first cloned horse was Prometea (Galli et al., Nature, August 2003) — carried, notably, by her own genetic twin. SCNT reconstructs an embryo from a donor somatic cell and an enucleated oocyte, followed by activation, culture, and transfer; in commercial equine practice it is offered by a small number of specialized laboratories (the Galli/Lazzari group's literature documents the OPU→ICSI→SCNT technical continuum), typically to preserve the genetics of geldings and deceased or castrated performance animals.

Governance: WOAH Code Chapter 4.12 addresses SCNT in production livestock and horses; breed registries differ sharply on registering clones and their offspring, and any client conversation begins with the destination registry's rules. Efficiency remains low relative to other ART (many reconstructed embryos per live foal), and programs represent that honestly. In cattle, cloning occupies the same specialized-service position (Trans Ova lineage services in North America), governed by the same WOAH chapter.

Micromanipulated equine embryos — biopsied for genetic testing, or blastocoel-collapsed for vitrification (§13) — occupy their own sanitary and procedural category: WOAH Code Chapter 4.10 covers micromanipulated oocytes and embryos from livestock and horses precisely because breaching the zona (or working through the capsule) changes the sanitary assurances that intact-embryo trade relies on (§4). The IETS certificate system likewise distinguishes micromanipulated material.

In the horse, biopsy is practiced clinically through the capsule, with technique documented in the Hinrichs-lineage and ICSI-program literature — equine micromanipulation is capsule-aware in a way bovine work never has to be. Three governing rules: it is performed under a validated SOP by qualified operators; the manipulated status travels on the embryo’s paperwork; and the sanitary category changes the moment the zona or capsule is breached.

The export pathway for any stallion-semen straw or mare embryo is determined by four questions answered before production: What species and product class (semen; in vivo derived embryo; IVP embryo; micromanipulated embryo)? What destination (which WOAH-aligned national requirements apply — EU under 2020/686, US imports under 9 CFR 98, exports per APHIS IREGS country files)? What establishment status (approved semen collection centre / embryo collection team / embryo production team where the destination requires it)? And what practitioner and establishment approvals (the AETA/CETA certification frameworks are bovine-centred; equine export paths rest chiefly on approved-establishment status and the health certification itself)?

The paperwork spine: IETS-format certificates (recovery, IVM/IVF, freezing) with straw identification per the freezing centre and the IETS certificate system, the sanitary processing record (species-appropriate processing per WOAH Ch. 4.8 and IETS guidance, exactly as certified — see §4), donor health testing per the destination's requirements, and the endorsed health certificate itself. The operational rule from §2 bears repeating because it is where programs fail: the destination determines the protocol, and the protocol must be in force at collection — export eligibility usually cannot be conferred on material retroactively.

The verified chronology — each entry carried by its register source, including the attribution corrections established during verification.

Primary authorities by section (full citations, tiers and verification status in the Animal ART Source Register, Ed. 1.0):

Revision control. This is Edition 1.0, the initial published edition (26 August 2026; a pre-publication external review is incorporated), maintained against Source Register Ed. 1.0 (94 sources, verified the same date). Scheduled re-verification triggers: any new WOAH Code edition; the IETS Manual edition-year confirmation; the annual IETS statistics release (S9); and AAEP guideline revisions (S16). Changes to procedure text require a source in the register at Tier A/B, or a new register entry verified to register standard.